SA
VRTX icon

SpiderRock Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

SpiderRock Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Hold
0
– -$5.26M – 166
2021
Q2 		– Hold
0
– – – 19
2021
Q1 		– Hold
0
– – – 11

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SpiderRock Advisors's VRTX Position: Q3 2024 in Review

SpiderRock Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 57% in Q3 2024, buying an estimated $507K and bringing the position to 2,898 shares worth $1.35M. The position accounts for 0.02% of the portfolio, ranked #406.

SpiderRock Advisors first reported a position in VRTX in Q1 2024 and has held it in 3 quarters since. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • SpiderRock Advisors held 2,898 shares of Vertex Pharmaceuticals worth $1.35M as of Q3 2024.
  • SpiderRock Advisors bought 1,055 Vertex Pharmaceuticals shares in Q3 2024, an estimated $507K.
  • Vertex Pharmaceuticals made up 0.02% of SpiderRock Advisors's portfolio in Q3 2024, its #406 holding.
  • SpiderRock Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.